By Mill Chart
Last update: Jan 2, 2024
Here's NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) for you, a growth stock our stock screener believes is undervalued. NYSE:NVO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. Let's break it down further.
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NYSE:NVO has earned a 7 for growth:
ChartMill employs its own Valuation Rating system for all stocks. This score, ranging from 0 to 10, is determined by evaluating different valuation factors, including price to earnings and free cash flow, both in absolute terms and relative to the market and industry. NYSE:NVO has earned a 5 for valuation:
To gauge a stock's financial health, ChartMill utilizes a Health Rating on a scale of 0 to 10. This comprehensive evaluation encompasses liquidity and solvency, both in absolute terms and in comparison to industry peers. NYSE:NVO has earned a 7 out of 10:
ChartMill assigns a Profitability Rating to every stock. This score ranges from 0 to 10 and evaluates the different profitability ratios and margins, both absolutely, but also relative to the industry peers. NYSE:NVO scores a 9 out of 10:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
Our latest full fundamental report of NVO contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (5/6/2024, 2:49:03 PM)
124.59
+1.54 (+1.25%)
The anti-obesity medication stock is way up, and there could be more fuel in the tank.
The company delivered solid quarterly results, but its discussion of an investigational drug is what really gave its shares a pop.
These under-the-radar stocks have the potential to reach a $1 trillion valuation by 2030 as they gain momentum in their respective industries.
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.
Amgen (AMGN) stock is soaring after the company's CEO said he was "very encouraged" by interim data for Amgen's new weight-loss drug.
Stock spinoffs can unlock shareholder value but management sometimes uses them to get rid of unwanted, slow-growing businesses.
The path is clear for even more growth from Novo Nordisk's top two drugs, Ozempic and Wegovy.
NVO earnings call for the period ending March 31, 2024.
NVO stock results show that Novo Nordisk beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Novo Nordisk stock came under mild selling pressure early Thursday, after the company reported Q1 results and lifted guidance.
We love it when our favorite clothes go on sale, so when the market offers us a deal, these are the stocks to buy on dips.